Mr. Markison has been with King Pharmaceuticals since 2004 and led the Company through to its recently announced acquisition by Pfizer for $3.6 billion. Previously Mr. Markison was with Bristol-Myers Squibb from 1982 to 2004, where he served in various commercial and executive positions rising from an oncology sales representative to become President, BMS Oncology/Virology and Oncology Therapeutics Network. Mr. Markison serves on the Board of Directors of Immunomedics, Inc., where he is Lead Director and Compensation Committee Chair. He also serves on the Board of Directors for the Komen Foundation and on the Board of Trustees for the Pennington School. Mr. Markison received a B.S. from Iona College in New Rochelle, N.Y.
"It is with great pleasure that we welcome Brian Markison to become associated with our Board. He brings significant expertise, both strategic and commercial, that will be invaluable to Rosetta as we advance the launch of the company's oncology diagnostics and develop our pipeline of diagnostics and biomarkers based on our proprietary microRNA technology," commented Yoav Z. Chelouche, Chairman of the Board.
Kenneth A. Berlin, President and CEO of Rosetta Genomics, welcomed Mr. Markison by saying, "We are delighted at the prospects of having Brian join our Board. We are certain to benefit from his vast industry experience, particularly in oncology. Brian's knowledge of the pharmaceutical markets and his many relationships will be a valuable asset as we build Rosetta into a leading molecular diagnostics company."